AVITA Medical Overview
AVITA Medical (RCEL) has a ROE of 195.71%, above the sector sector average of -4.47%.
Get informed when a big investor buys or sells
+ Follow195.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RCEL is 195.71%. That is above the sector sector average of -4.47%. Investors often review this figure alongside AVITA Medical's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, RCEL currently prints 195.71% for ROE, while the sector average sits near -4.47%. That is roughly 4480.0% above the sector mean. Large gaps often invite a closer look at AVITA Medical's growth, margins, and balance sheet.
Return on Equity shows how effectively AVITA Medical converts resources into returns. At 195.71%, RCEL may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RCEL's ROE (195.71%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
